IN2014DN07410A - - Google Patents

Info

Publication number
IN2014DN07410A
IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
inhibitor
prodrug
relates
pharmaceutical combination
Prior art date
Application number
Other languages
English (en)
Inventor
Ralph Tiedt
Alan Buckler
Fred Harbinski
Sneha Sanghavi
Douglas Jeffery
Christopher Wilson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN07410A publication Critical patent/IN2014DN07410A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN7410DEN2014 2012-04-03 2013-04-01 IN2014DN07410A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
IN2014DN07410A true IN2014DN07410A (th) 2015-04-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7410DEN2014 IN2014DN07410A (th) 2012-04-03 2013-04-01

Country Status (11)

Country Link
US (1) US20150051210A1 (th)
EP (1) EP2833917A1 (th)
JP (1) JP2015512447A (th)
KR (1) KR20140146086A (th)
CN (1) CN104244982A (th)
AU (1) AU2013243737B2 (th)
CA (1) CA2866321A1 (th)
IN (1) IN2014DN07410A (th)
MX (1) MX2014011987A (th)
RU (1) RU2014143213A (th)
WO (1) WO2013151913A1 (th)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3848034B1 (en) * 2014-03-26 2025-02-12 Astex Therapeutics Limited Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
MX373272B (es) * 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
MY159523A (en) 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
AU2007309149C1 (en) 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
DK2076289T3 (da) * 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
KR101660544B1 (ko) * 2008-04-29 2016-09-27 노파르티스 아게 섬유모세포 성장 인자 수용체의 키나제 활성에 대한 조정을 모니터링하는 방법 및 상기 방법의 용도
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Also Published As

Publication number Publication date
CN104244982A (zh) 2014-12-24
KR20140146086A (ko) 2014-12-24
RU2014143213A (ru) 2016-05-27
JP2015512447A (ja) 2015-04-27
MX2014011987A (es) 2014-11-10
WO2013151913A1 (en) 2013-10-10
CA2866321A1 (en) 2013-10-10
AU2013243737A1 (en) 2014-09-25
AU2013243737B2 (en) 2016-06-30
US20150051210A1 (en) 2015-02-19
EP2833917A1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
IN2015DN00598A (th)
IN2014DN10670A (th)
MX2015002040A (es) Baricitinib deuterado.
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
MA39749A (fr) Dérivés de pipéridine-dione
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
PH12015502091A1 (en) Cdc7 inhibitors
EP2980585A4 (en) Vital stain
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
EP3019166A4 (en) A pharmaceutical combination for the treatment of melanoma
MX2015008829A (es) Momelotinib deuterado.
IN2014DN07996A (th)
IN2014DN06738A (th)
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
EP3192511A4 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
IN2014DN07410A (th)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
NZ717192A (en) Anti-inflammatory tripeptides
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
EP3166405A4 (en) 3'-substituted-abscisic acid derivatives
MX2015012610A (es) Pacritinib deuterizado.
EP3069326A4 (en) Modular product vending system
EP3016535A4 (en) Modular impact protection system for athletic wear
HK40007630A (en) Aliphatic prolinamide derivatives
AU334998S (en) Jewellery